Proficio Capital Partners LLC Acquires New Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Proficio Capital Partners LLC acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 35,609 shares of the company's stock, valued at approximately $2,915,000.

A number of other institutional investors have also modified their holdings of the stock. Natixis Advisors LLC grew its position in shares of Vaxcyte by 61.1% during the 3rd quarter. Natixis Advisors LLC now owns 22,697 shares of the company's stock valued at $2,594,000 after acquiring an additional 8,606 shares during the period. Diversified Trust Co acquired a new stake in shares of Vaxcyte during the 4th quarter valued at about $1,433,000. China Universal Asset Management Co. Ltd. grew its position in shares of Vaxcyte by 23.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock valued at $2,163,000 after acquiring an additional 4,962 shares during the period. Citigroup Inc. grew its position in shares of Vaxcyte by 33.0% during the 3rd quarter. Citigroup Inc. now owns 220,543 shares of the company's stock valued at $25,201,000 after acquiring an additional 54,748 shares during the period. Finally, TimesSquare Capital Management LLC grew its position in shares of Vaxcyte by 53.7% during the 4th quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock valued at $33,860,000 after acquiring an additional 144,516 shares during the period. Hedge funds and other institutional investors own 96.78% of the company's stock.

Insider Transactions at Vaxcyte

In other news, Director Teri Loxam sold 6,250 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jim Wassil sold 8,000 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00. Following the sale, the chief operating officer now owns 205,695 shares of the company's stock, valued at $17,208,443.70. This trade represents a 3.74 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 46,250 shares of company stock valued at $3,840,018. 3.10% of the stock is currently owned by company insiders.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PCVX shares. Guggenheim reiterated a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, March 12th. The Goldman Sachs Group assumed coverage on Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 price target for the company. Finally, Needham & Company LLC restated a "buy" rating and issued a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $147.50.

Vaxcyte Price Performance

PCVX traded up $0.20 during trading hours on Friday, reaching $74.66. The company's stock had a trading volume of 1,778,118 shares, compared to its average volume of 933,591. Vaxcyte, Inc. has a fifty-two week low of $58.10 and a fifty-two week high of $121.06. The stock has a market cap of $9.61 billion, a PE ratio of -16.23 and a beta of 1.02. The business's 50-day moving average is $81.41 and its 200-day moving average is $94.10.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. Analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.